Pharmaceuticals, Biotechnology and Life Sciences
DARTMOUTH, Nova Scotia–(BUSINESS WIRE)–IMV Inc. (Nasdaq: IMV) (TSX: IMV), a clinical-stage biopharmaceutical company (the “Company” or “IMV”), today provided updates…
N4 Pharma will test a Covid-19 DNA plasmid if Nuvec, a novel delivery system for cancer treatments and vaccines, can be used as a delivery system by potential collaboration partners developing Covid-19 DNA or RNA vaccines.
You want to do what is excellent for your kids. You know about the importance of baby gates, car seats, and other ways to keep them secure. But, did you know that the most excellent way to protect your kids is to make sure they have all of their vaccinations?
EUCRISA is the first and only 100% steroid-free, topical prescription medication approved for patients as young as 3 months of…
Novavax published positive top-line results of its pivotal Phase 3 clinical trial of NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with its proprietary Matrix-M adjuvant, in adults aged 65 and older.
Roche said Tuesday it started testing Actemra (tocilizumab) with the Biomedical Advanced Research and Development Authority (BARDA)on top of standard of care in hospitalised adult patients with severe COVID-19 pneumonia compared to placebo on top of standard of care.
European site enrollment concerns grow to 85% NORTHBROOK, Ill.–(BUSINESS WIRE)–#COVID19–Over the course of just one week, US clinical research study…
ObsEva CEO Ernest Loumaye s said the instituting new measures to support the priorities of safety to manage through the COVID-19 pandemic.
The U.S. Food and Drug Administration is actively and aggressively monitoring the market for any firms marketing products with fraudulent coronavirus (COVID-19) diagnostic, prevention and treatment claims as part of our ongoing efforts to protect public health during this pandemic. As a result of these activities, the agency is beginning to see unauthorized fraudulent test kits that are being marketed to test for COVID-19 in the home.
Teva said it will donate 6 Million tablets through wholesalers to hospitals by March 31, and more than 10 Million within a month, to meet the urgent demand for the medicine as an investigational target to treat COVID-19.